The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer

CompletedOBSERVATIONAL
Enrollment

85

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Gastric CancerComplement Component DeficiencySurgery
Interventions
PROCEDURE

gastrectomy plus D2 lymphadenectomy

A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.

DRUG

S-1+Oxaliplatin

"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid,po, Day1\~14 (S-1:BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid)~* Oxaliplatin: 130mg/m2,iv drip for 2h,Day1"

Trial Locations (1)

510000

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT02425930 - The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter